Derma Sciences (DSCI) Prelim. Q4, FY15 Sale Miss Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Intel shares fall as competitor reports record results
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- AMD forecast eases AI spending fears as data-center sales surge
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Derma Sciences Provides 2015 Preliminary Net Sales and Introduces 2016 Financial Guidance
January 7, 2016 7:30 AM ESTReduces non-R&D operating expenses by approximately $10.0 million through workforce reductions, expense cuts and cost-savings initiatives Expects 13% AWC growth in 2016 and positive cash flow for the second half of the year
PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, provides preliminary net sales for the year ended December 31, 2015, announces various actions to reduce operating expenses and introduces financial guidance for the year ending December 31, 2016.
For the year ended December 31, 2015:
... More


